anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A attenuated pseudomonasaeruginosa isolate especially CFCPA 30720 is disclosed for formulating vaccine curing or preventing pseudomonas contagion. Pseudomonasaeruginosa isolate is extracted from the infected patient and classified into 7 classes by Fisher-Devilin immunotype; only type 3 germ is selected, repeatedly dosed to experimental animals and acclimatized to yield attenuated pseudomonasaeruginosa isolate CFCPA 30720 (KCCM 10031) which is not toxic in itself and attenuated for the cell wall protein to yield only antigen. Type 3 isolate is selected as the objective isolate on the basis that it is detected from the blood of more than 20% of pseudomonas infected patients. The acclimation to yield the attenuated pseudomonasaeruginosa isolate is repeated, commonly 3-7 times, until it shows the desired value of LD50. The desired LD50 value is more than 2.0 x 107 ,desirably 2.5 x 108 cells. CFCPA 30720 can be used for preparing pseudomonasaeruginosa vaccine by nurturing the germs in various sized fermenters having an optimum environment; yielding many isolates; treating the isolates by a series of processes; yielding cell wall protein; and finally treating them by ordinary vaccine preparation methods.
Because of the possibility of cross-sensitivity, fluphenazine decanoate should be used cautiously in patients who have developed cholestatic jaundice, dermatoses, or other allergic reactions to phenothiazine derivatives.

Psychotic patients on large doses of a phenothiazine drug who are undergoing surgery should be watched carefully for possible hypotensive phenomena. Moreover, it should be remembered that reduced amounts of anesthetics or CNS depressants may be necessary.

The effects of atropine may be potentiated in some patients receiving fluphenazine because of added anticholinergic effects.

Fluphenazine decanoate should be used cautiously in patients exposed to extreme heat or phosphorus insecticides.

The preparation should be used with caution in patients with a history of convulsive disorders, since grand mal convulsions have been known to occur.

Use with caution in patients with special medical disorders such as mitral insufficiency or other cardiovascular disease and pheochromocytoma.

The possibility of liver damage, pigmentary retinopathy, lenticular and corneal deposits, and development of irreversible dyskinesia should be remembered when patients are on prolonged therapy.

Outside state hospitals or other psychiatric institutions, fluphenazine decanoate should be administered under the direction of a physician experienced in the clinical use of psychotropic drugs, particularly phenothiazine derivatives. Furthermore, facilities should be available for periodic checking of hepatic function, renal function, and the blood picture. Renal function of patients on long-term therapy should be monitored; if blood urea nitrogen (BUN) becomes abnormal, treatment should be discontinued.

As with any phenothiazine, the physician should be alert to the possible development of “silent pneumonias” in patients under treatment with fluphenazine decanoate.

Neuroleptic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent , a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of neuroleptic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. in vitro
Crohn's disease (CD) patients can have a chronic, relapsing course with frequent flares despite aggressive therapy. Flares are often difficult to predict. The goal of disease monitoring is to identify patients at risk for flare in order to treat earlier, with the hope of maintaining remission and avoiding irreversible bowel damage such as fistulas and strictures that may lead to surgery. Although endoscopic visualization of the mucosa allows in some cases ability to predict flare and determine deep remission, this procedure is invasive and requires anesthesia and a bowel preparation, and is not without risk. Abdominal pain, cramps and diarrhea are particularly common symptoms of CD, which are associated with alteration of gastrointestinal (GI) motility. Thus better understanding of GI motility patterns in CD flare and remission states may be helpful for prediction of flare for guiding appropriate therapy.

The goal of this study is to determine whether the motility patterns measured by the G-Tech non-invasive, wireless patch system can provide useful insight for routine CD care. Three G-Tech patches will be placed on the patients' abdomen and they will be given an iPod Touch to carry with them for the next 3-6 days. Data from the patches is processed offline to obtain motility patterns of the stomach, small intestine and colon. These patterns represent a rich trove of data that can be studied in multiple ways to provide comparisons and insight. Some examples are the overall strength of motor activity in each of the organs, the duration and rhythmicity, the correlation with meals, pain events and bowel movements, day to day variations and their correlation with symptoms, and diurnal effects.
FIELD: medicine, cardiology. SUBSTANCE: invention relates to methods for selection of optimal dose of unfractionated heparin (UFH) in subcutaneous administration in patients with acute coronary syndrome without rise of segment ST value. Treatment is carried out after intravenous administration of UFH in the dose 5 000 U and determination of value APTT (activated partial thromboplastin time) each 6 h after administration of UFH. At value APTT less 40 s UFH is administrated in the dose 12 500 U; at value APTT 40-49 s 10 000 U; at value APTT 50-75 s 7 500 U; at value APTT 76-85 s 5 000 U; at value APTT 86-100 s 2 500 U; at value APTT 101-150 s 2 500 U. At value APTT above 150 s UFH is not administrated and additional control of APTT is carried out in 3 h. Then UFH is administrated in the dose in value APTT less 40 s 12 500 U; at value APTT 40-49 s 10 000 U; at value APTT 50-75 s 7 500 U; at value APTT 76-85 s 5 000 U; at value APTT 86-100 s 2 500 U; at value APTT 101-150 s 2 500 U. Method provides reducing risk of bleeding and development of unfavorable coronary events. EFFECT: improved treatment method. 1 tbl, 1 ex
Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) can be delivered to antigen presenting cells. In various embodiments of the present invention, the STAVs can be delivered in lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers Nano-STAVs into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity. The STAV formulations can be introduced into solid tumors present in the mammal. Alternatively, the Nano-STAVs can be introduced through direct inoculation. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.
BACKGROUND: Pre-eclampsia is a syndrome that chiefly includes the development of new-onset hypertension and proteinuria after 20 weeks of pregnancy. Pre-eclampsia is one of the major causes of mortality and morbidity in Nepal. Hyperhomocysteinemia may be a cause of the endothelial dysfunction provoked by oxidative stress in pre-eclampsia. This study was designed to evaluate the association of homocysteine with Vitamin B12 and folate in patients with pre-eclampsia.
METHOD: An observational cross sectional study was performed in the Gynecology and Obstetrics Department of TUTH involving seventy two subjects with pre-eclampsia. Blood pressure, urinary protein levels, serum homocysteine, Vitamin B12 and folate levels were compared in both mild and severe forms of pre-eclampsia. Concentration of Vitamin B12 and folate were measured using Vitros ECI and homocysteine was measured using CLIA. SPSS 23.0 was used to analyze the data. Tests were performed with Mann Whitney Test and Spearman's rank correlation test. A p-value < 0.05 was considered statistically significant.
RESULTS: This study showed no significant difference in age and weeks of gestation in both mild and severe forms of pre-eclampsia. Mean concentration of homocysteine was higher (13.1 ± 6.4 micromol/L) in severe Pre-eclampsia as compared to mild cases (7.6 ± 2.8 micromol/L). Mean concentration of folate was lower in severe cases (35.4 ± 24.1 micromol/L) when compared with mild cases of pre-eclampsia (57 ± 23.4 micromol/L).
CONCLUSION: Homocysteine levels were increased in severe Pre-eclampsia when compared with mild pre-eclampsia and this finding can be used to predict and prevent complications in patients with pre-eclampsia.
The purpose of this study is to determine the bioavailability of 0.5mg dutasteride in a novel formulation compared to the currently marketed 0.5mg dutasteride soft gel capsule in fasted healthy male subjects. This will be an open-label, single dose, randomized, two-period crossover study in healthy male subjects. Subjects will receive a single oral dose 0.5mg novel dutasteride formulation and a single oral dose 0.5mg dutasteride soft gel capsule in a fasted state. Each dose of the study medication will be separated by a 28-day washout period. Blood samples for pharmacokinetic analysis will be taken at regular intervals after dosing. Safety will be assessed by measurement of blood pressure, heart rate, laboratory data, and review of adverse events. The study will enrol approximately 35 healthy male subjects to ensure that 30 subjects complete the study. The study will be conducted in the USA.
Disclosed herein are an N-terminal functionalization-modified cystyl dioleylamine compound, a chemical synthesis method therefor, and use thereof. A central skeleton of the compound is cystine; a cystine carboxyl terminal is modified with oleylamine to form a double hydrophobic tail chain structure; an amino terminal is modified with a functionalized hydrophilic head including an amino acid with a positive electricity center or an aromatic ring structure and a polypeptide fragment. A structural general formula is as shown below. The cystine central skeleton structure comprises a disulfide bond, such that the molecule has a reduction-sensitive property, and an overall structure of the hydrophobic tail chain and the hydrophilic head of the molecule determines that the molecule is amphipathic and can be self-assembled in water and other systems. A cationic charge center comprised in the hydrophilic head can form an electrical effect with a target nucleic acid so as to encapsulate the nucleic acid, thereby playing a role in nucleic acid delivery. The N-terminal functionalization-modified cystyl dioleylamine compound provided by the present invention, as a novel lipid material or an auxiliary lipid material, can efficiently deliver a nucleic acid compound into a cell, and has huge potential in the field of gene therapy.
MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
The vaccine is inactivated by ethanol and is harmless. Theantigene for its preparation is produced after cultivation underroller conditions of the local cellular cultural strain DD/94 ofcells of the permanent line VIC21. The viral suspension producedwith infection titre 107.5 KID50 is adsorbed in 2% gel ofaliminium hydroxide and is settling for 48 h, after which thesupernatant is removed to 50% of the initial volume and isinactivated by ethanol. As an oleoadjuvant to the antigene mineraloil emulsified by montanide 888 is added in 3:2 ratio. Theimmunogeneity of the vaccine is tested on 18-20-week chicksimmunized with live vaccine in advance. On the 25th day after thevaccination a group of 10 chicks are infested by a virulent strainof the fowl pest virus. Simultaneoulsy a control group of 10unvaccined chicks is also infested. For 15 days 90% of thevaccined chicks remain in good health, and 90% of the controls diewith symptoms of fowl pest.2 claims.
PURPOSE:To provide the subject agent having excellent skin-protective effect, powerful in medicinal bathing effect, thus effective for intractable dermatoses, etc., also free from side effects, nontoxic even if swallowed, and inert to bathtubs, etc., because of containing no various additives. CONSTITUTION:The objective bathing/medicinal bathing agent contains, as active ingredient, an extract of Asparasus linearis, a kind of naturally occurring leguminous plant. This active ingredient can be obtained by (A) extracting the leaves or stems of the above plant with water and/or an organic solvent followed by distilling off the solvent, or (B) grinding the leaves or stems of the above plant. Or, the extract may be obtained by a similar method to that for conventionally producing green tea or tea. For the amount of this agent to be used in a bathtub, which is dependent on the kind or degree of a disease, it is preferable that 2-10g of the dry leaves of the above plant be used based on a bathtub of 200l volume. This agent has the advantages owing to the minerals contained in the above plant, can give beautiful and smooth skin by bathing, also has such effects as to be recovered from fatigue, and can cure the above-mentioned diseases without side effects.
Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
We propose a sample collection registry protocol for use in obtaining biologic and environmental samples anonymously from adult volunteers for use in laboratory assay evaluation. The samples will be used to determine if new tests are sufficiently valid and precise to be used in research studies and for quality control purposes. In studies involving the storage and analysis of laboratory specimens, it is essential to evaluate the performance of available assays and to actively assess the impact of storage and handling on the quality of samples and laboratory analyses. Specifically, it is essential to 1) demonstrate that an assay is sufficiently reproducible and stable over time such that differences in levels among individuals in the population can be detected; 2) evaluate assay reliability by sending blinded anonymous samples along with study samples to testing labs for quality control purposes; 3) test proposed laboratories or methods by using replicate samples from the population in order to choose the laboratory or method with the greater precision, and; 4) assess how sample collection, handling, and storage procedures affect measured levels of specific analytes to allow for informed decisions about whether to proceed with a specific analysis. Under this protocol, assays could include evaluation of immunologic parameters, genes and gene products, peptides, proteins, hormones, lipids, viability of cells, evaporation and dilution effects, chemical toxins and their metabolites, micronutrients, metals and more. For some samples, lymphocytes will be extracted for use in studies of lymphocytes and/or immortalized cells. Samples to be collected will include blood, urine, saliva, household dust, cheek cells, hair, nasal cells, stool, nail clippings, exhaled breath condensate, sperm samples, skin cells, and/or sputum. In addition, a pulmonary function test (PFT) may be conducted to collect lung function information. Since it is important to collect samples from the general population, this protocol covers collection of samples from non-pregnant adults (male and female, age 18+). Specimens may be collected during a one-time sample collection, or participants may be asked to provide specimens on several occasions over a specified period, not to exceed one year.
Disclosed is a graphical user interface for displaying a patient’s medical information such that a user can readily view a graphical display of a wellness of the patient. The graphical display shows a score for a first category that relates to a first system of the patient’s body and scores for multiple subcategories from a first subcategory set. The subcategories of the first subcategory set each relate to at least one of a scorable feature, attribute, and component of the first system. The graphical user interface comprises a dynamic display. The dynamic display comprises a first graphical representation and a second graphical representation. The first graphical representation depicts at least one of the scores for the subcategories of the first subcategory set. The first graphical representation comprises a graphical depiction of at least one of a human body, a portion of the human body, and a tree structure. The second graphical representation depicts the score for the first category relating to the first system of the patient’s body. The score for the first category is hierarchically related to the subcategories of the first subcategory set in that the score for the first category is generated by combining the scores for the subcategories of the first subcategory set. The score for the first category is selectable on the graphical user interface via user input such that selection of the score for the first category causes the graphical user interface to display at least one of the first graphical representation and the scores for the subcategories of the first subcategory set from which the score of the first category was generated.
The method is used for cloning a mouse-derived VEGF-2 (mVEGF-2) gene from an impregnate mouse embryo and then cloning a human-derived VEGF promotor (hVEGF promoter) from a newborn placenta, and the mVEGF-2 is driven by the hVEGF promoter and  inserted into an expression vector pEGSH of a mammal so that a vector pEGVPV which generates a large amount of DNA in a prokaryotic cell at a high copy number and both are expressed in a prokaryon and a mammalian cell can be established. After the vector is converted into E. coli DH5 alpha, the obtained DNA copying number is more than 2000/cell, and the DNA output separated from a cell culture can achieve 1.5 mg/l. The present invention also provides a method for producing vascular endothelial growth factor-2 (VEGF-2) DNA medicine by microorganisms. The vascular endothelial growth factor can specially act on a vascular endothelial cell to intensely promote cell proliferation and vascularization, and the vascular endothelial growth factor has the function of enhancing vascular permeability. An ischemic animal model experiment indicates that the naked DNA can promote neovascularization and enhance the establishment of collateral circulation when microinjected to a tissue with ischemia so as to effectively improve the blood supply of the ischemic tissue. The method can provide a new scheme for treating vascular diseases.
This article explores the interpreter's role and approaches to working with deaf students as seen from deaf individuals' and interpreters' perspectives. A group of 41 formerly mainstreamed deaf individuals and interpreters offered insights into how the interpreter's role in mainstream classrooms influences deaf student autonomy and participation. This research illustrates the significance of autonomy for mainstreamed deaf students and suggests a correlation between the interpreter's role and deaf students' perceived autonomy in the classroom. In addition, the findings suggest that deaf students do not always know what an interpreter is supposed to do in K-12 classrooms. This study also finds that educational team members do not always explicitly communicate their roles and responsibilities to deaf students, leading to confusion that impacts their autonomy and overall experience. Finally, this research finds that deaf students are not trained with the ability to negotiate and renegotiate the interpreter's role. This article concludes with considerations and recommendations for deaf education and interpreter education communities.
An injectable smart gel and the fabricating method thereof is provided. By adding a polymer electrolyte or a basic structural stabilizer, and a diluted solution in a modified chitosan, while the chitosan solution adjusted to neutral pH value that closing to the body. The chitosan solution flows at low temperatures to form a chitosan sol, and is solidified at body temperatures to form a chitosan gel. Therefore, the injectable smart gel is obtained. The injectable smart gel is not only injectable, meanwhile, is used as a magnetic nanoparticles capsule with drug molecules for drug delivery gel. By applying the external magnetic field, the electric field, ultrasonic waves or the other method with non-contact forces, the capsule rupture is controlled to released rugs to the injectable smart gel for long-acting and multi-stages drug delivery. The present invention is highly valuable in the biomedical engineering.
Hallux valgus (HV) is the most common deformity in the adult forefoot. Characterizing and classifying HV primarily has been based on weightbearing radiographic imaging. Understanding of this pathologic process has mainly been confined to two planes, where the dominating modality of choice has been assessment by antero-posterior (AP) and lateral radiographs. From these two projections, imaging parameters have developed to define the severity of HV. With this understanding as the basis for describing the deformity, more than 140 operative techniques have been described. Although many of these techniques are of historical interest only, consistently favourable outcomes remain elusive even among more popular current techniques. HV corrective surgery is known to have mediocre results, with recurrence rate as high as 30-70%. Unsuccessful treatment of the condition is amongst the most common in the Norwegian patient injury compensation scheme. The variation in corrective techniques and the associated persistent and clinically significant rates of poor outcomes may indicate an incomplete treatment of the pathoanatomy of HV. Numerous recent publications have proved that the hallux valgus deformity should be viewed as a three-dimensional deformity. These recent studies have also pointed out new radiological parameters in AP and axial view, focusing on the multiplanar understanding of the deformity. The key challenge of the hallux valgus foot is the lack of clear guidelines for choosing the best treatment to these large group of patients. There is of today no guidelines nor consensus considering the indication for surgical treatment of the hallux valgus deformity. It is not known how much nuisance the patient should present before surgery could be worthwhile. Many studies have been made in the field of HV, but literature with the focus on comparing the surgical correction and the patient related clinical outcome is sparse and insufficient.

In this project the investigators primary aim is to investigate radiological and clinical factors that predict outcome in participants operated for hallux valgus deformity.